joining Good morning, and thank morning. all you us this for
commercial shared and drive VASCEPA quarter, in Last diversification; X-dimensional you operational I for quarter the to toward awareness critical and and in well commercializing successful we including over enhance progress to risk cardiometabolic at-risk our to XXXX VASCEPA/VAZKEPA player to Amarin, its for strides goal in go-to-market that the the I or taken to Europe mid-September. we by evolution. with made reduction number world. product our for make led continue was highlighted patients Today, of our demonstrating strategy a transformative The CEO indication. important report bring cardiovascular position, on benefits the These depth to of achievements third we I'm just become underscores CV vision geographic risk had the the strategy: in VAZKEPA quarter market. the commitment as the strategy, progress growth the U.S., Germany when representing around advances breadth, on designed branded were a our are height, way the the by milestone And executing demand meaningful to reduction made it's launch our our announcement by as This envision. U.S. was we've global happy in of followed expansion; we which
of morning, for review net press revenue we our with is million release revenue results months begin compared million of first me with million this quarter total VASCEPA. saw you a of The quarter. revenue our the of We of reported in $XXX.X XXXX. in year-to-date Let U.S. for total period $XXX X bulk reported Starting same the XXXX. sales product As of for this third the in million of $XXX.X brief $XXX.X revenue: with our XXXX third with compared net the from
our support remains the Mike expansion in discuss growth U.S. VASCEPA later plans. sheet, franchise continues to our will profitable, as our and and and Importantly, call, strong along balance with
dive a a particularly been potential the the Now for deeper quarter, U.S. market market. the for of competitive This into number growth impeded a U.S. has as dynamics in and challenging
First, quarter. the to X% the visits caused and the impact lab research with variant X%, of COVID-XX visits compared prior and and by patient respectively, Delta drop
lipid the the weeks first market Additionally, quarter. X of flattened for the
time, factors let first better to so through COVID-XX quarter. pandemic hit, indication and access VASCEPA to to dynamics risk before driver the thinking. them. on for of the for building for is for access reduction Long reevaluate key you improving more Perhaps the plan a the and available physicians physician the decline. its and our cardiovascular understand growth on our opportunity generics created develop We biggest engagement. to market These the an significant was tackle X adoption and me the to the there walk entire to gating Finally both strategy, were need needed
For physicians XX%. end X. example, fallen the out of to to Access according Monitor, to By XXXX or that approximately XXXX, was access X of about XX% ZS' had in access
field In days and in X out physicians the other X near on accessible words, for early the at of XXXX, is quarantine those the X%; they by currently During at force. only of less visits stand were levels average XX%. than
more. number We the enhancing strategy impactful VASCEPA e-mail branded allowing in in-person include platforms medical employs care visits campaigns, they almost provider risk detailing, by CV efforts CMEs, model of messaging and XXX,XXX offerings reach significantly and use U.S. a and virtual to regarding portals, of through educational this new of reach want. with and platforms them Simply, drive our to in prescribers websites our our as ways and increase target customized high-frequency, prescribers robust VASCEPA for with patient's greater customer digital and use of benefits digital engagement to creates far digital the reduction. intend care significant statin the variety optimizing to health omnichannel and digital us a approach health force enhance efficiencies these the of our improve sales to to the These a professionals, integrate engagement and Our media promotional social a of such
of managed is area care. focus next Our
While exclusive several prescription we access improve Medicare patients real icosapent Part ethyl VASCEPA payers and with to need. as to VASCEPA D commercial intensifying currently remaining product, cover to the efforts are large remove barriers to medical
access. drive in growth are ability focus to continuing by volume We confident payer enhancing on our to further
not Finally, risk our between VASCEPA reduction. last, focus for approved in clarify to Generics difference of indications is area the generics. the important equally FDA cardiovascular are approved and
by the generics market particularly and VASCEPA indication eliminate of taking for educate pharmacy are uses, level. regarding non-indicated the limited the substitution We a the to the of created of variety steps generics at confusion with
to for minimize enhancing we to all continue within end our from progress. some references and reduce U.S. inaccuracies optimizing underscores narrow generics prescribing compendia Our correct factual and expanding complex managed by that VASCEPA care. X time, the goal improvement: of physicians in non-indicated usage the retail substitution pharmacy Correcting to in are access risk prescription to we September, announced And believe we used our areas a and in CV ecosystem what significant commitment platforms key but will is for total is label e-prescribing approved their difference and market care go-to-market order addresses above. the physician be for transformative systems systems, the reduction. to we uses for disruption a the it will making can these keeping any patient expect strategy, take process. And access, At within we which engagement make to
flow end-to-end to to goal ensure prescription Our prescriber to deliver patient is and a streamlined manage optimized experience. of simple an user and platform
driving a of purpose our these focused are decisions. while While new the early their with implementation tracking in and sense initiatives we will go-to-market days, be reevaluating
prescription resulting forward go-to-market We usage, increases? reporting expected impact. will measurements in these are by confident urgently Did as these all it for unfolds. successfully we be strategy this successful We Revenue. and impact? deliver revenue on and measurements did this ultimately, have success: that more look X initiatives provider Did produce front to And patient Strategic and and their new they implement greater initiatives? execution.
We versus to successful, allow initiatives also entertain and could which, if continue differentiate us strategic generics. to numerous consider further the feasible and
believe early generics aimed efforts U.S. significant ourselves the While on would future impact stages, that such versus have potential at in the truly differentiating a we in VASCEPA of
in our to now Europe. progress Turning
the in third VAZKEPA demonstrated global to Amarin a quarter, Germany. of commitment During commercial its becoming its launch player with
it entities in a patient with regulatory announcement, we that is a have population that year a As not over Today, since self-launch We Ireland, consistent announced little Europe, no just no VAZKEPA. label had commercial Europe reminder, an August broad the EMA-approved when REDUCE-IT. legal have presence. of X in no beyond totally for even infrastructure XXXX in we and did Amarin that would approval
including XXX our branches, Zug, XX commercial and employees; have We launch Germany. initial commercial a in hub legal in and executed entities have Switzerland;
medical are more scientific professionals that We for by proactive top launch we with the a and leaders events illustrated were both to of a Germany our XX by limited in continent. able launch days will to every to our renowned these than proxy Germany to and year-end. our VAZKEPA engage, audience. cardioprotective introducing and strides is market stream virtually, teams physicians successful specialists have The to ready the team This targeted events on and a more is the to our from promote an to and across hospitals endorsement execute schedule. early our societies; very believe and was especially ability and and successful was care And XX reach in such many thought expedited be led the physically live with great in a next effort the from The made conference physicians quarters, pleased to target hosted and more attended German internationally debuted access plan. launch to before for health that Germany, scientific teams COVID. to date cardiovascular the educate with by In of benefits best than as audience person XX making approved commercial and XXX the VAZKEPA couple key is still due
small in We time so the Galenus to or is portion prize included X be have a COVID-XX paper we prescriptions achieved of important German product We VAZKEPA achievement is step Prix Pfizer, submission. Prize are been awarded very the finalists making Pergamon their quarterly more scientific for in as X. readily the Germany, went the effective This Von of report today. recognized which an particularly represent prestigious October Galien X prescribing medicinal for innovative to prescriptions in widely were honored been that at total has electronic pleased updated been are approved BioNTech, for Germany's VASCEPA of accessible, second This for to in we have press. vaccine, place to honored has a Germany in a prize truly year's that and this system,
We the negotiation of file on communicated XX initiate to all Now France, goal are previously Denmark, Those Netherlands. our Amarin report access the XX. market level. markets already proud to process XX dossiers and allows really that Spain, is largest have regional This with Europe. I'm to by U.K., a Italy, we in year-end, Sweden, reimbursement submitted the that Finland, markets agencies Germany, the and Norway European
based country-specific monthly. uniqueness the included The have next on of I now for we data next and pricing various initiated data confirm lines exchanges several can our perspective, and list VAZKEPA the being XXX also will countries approximately the targeted that patient wave update an and time is We engaged submissions in population EUR will approvals. with define calls, on to in expected these of scientific demonstrating earnings the or eligible extensively already from include additional same X and label a reimbursement all countries, demographic submissions provide $XXX country of of XX Europe. our
Eastern We initiated we or Greece. steps the identify first have countries, to with the plan in also the to collaborate partners Europe partner Central with starting
same been have agile, the time in in and in investments prudent the yet fast year, Over how at we past we infrastructure measured built Europe. have
focused a treatment the belief in paradigm tremendous organization to markets change driven that care across by Europe. our our preventative opportunity exists structuring cardiovascular way, and prioritizing are in We a
cardioprotective X-launch in of relationships access. phase, Germany, important vast education on that the the of means our and establishing the majority targeted professionals market we are providing we negotiating Beyond markets, health which care with benefits VAZKEPA are in
customers differently be aligned an strategy successfully face-to-face the digital-first developed tailored our each us and quickly not all to implementing of and efforts. cross-functional behind ecosystem technology easily we've the of same, The customer We are to the it bespoke. market one approach Our us navigate recognize all to our allows to enables single channels model us complementing allow that markets individual field that must our integrate force and and commercial access in capabilities adapted and our have be while the to and digital engagement can plan. our specificities
excited about VAZKEPA that problem in as per health Union every very the common are and million the We for billion deaths increasingly year. Europe, year in CVD Europe opportunity causes an is XXX costs EUR X.X European
Our across Europe of cardiovascular we're residual risk is for mission small to rethink the treatment challenge. but the feat, no up
We are a of won't in the a lives to new Setting high-risk new across CVD. standard Europe committed cardioprotective establishing treatment patients improving for happen cardiovascular care by overnight.
and got the the a confidence to that have the the strategy happen. high people level of it we've evidence, we However, make drive, scientific
to pursuing. me we ambition of XX the have worldwide. access approximately cardioprotective strategy and We to the the Last other are have let to currently turn mapped multibillion-dollar benefits international the we of the Beyond top Europe, in markets markets significant XX. cardiometabolic obtain in XX opportunities these now our to quarter, access other bring announced market VASCEPA/VAZKEPA to potential our
Our will take ways. in plan X place
Israel. plan when filings begin XXXX, to and up product regulatory and including will obtain The Australia, New we X countries, to in approval in first submit Zealand
second when The wave to X up we come seek will in will in countries. XXXX, approvals
of study and for we the follows will approvals be FDA by will XXXX, the cardiovascular third approvals VASCEPA/VAZKEPA when be EMA risk the countries remaining targeted. from cardiovascular The we These in reduction data in supported have the wave long-term indication. X all filings REDUCE-IT outcome and seeking
Such language be specifically broad these label have of advantage the will of marketing partnership. EMA our collaborations In potentially We most will giving we all our opt for these optionality in seeking a reach agency CV authorization has We providing control of countries. of over markets, to an the us markets event the as these expanding additional and millions the a represents of at Amarin to and billion. opportunity globally. potential of patients business benefit grow of $X around product we market XX believe distributorship risk
where China of have end VASCEPA Kong receive XXXX. markets the to international partner, to other in continues partners. Edding, approval and to we on China, Hong of Moving already near our In expect Mainland
in With Edding launch XXXX. these these approvals, has in territories plans to
As X in Europe, the U.S. the launch Chinese will with the support societies. and key VASCEPA of cardiology
for and and in for good Pfizer known this the pharmaceutical for statins well sales more billion, physician will new need in well collectively in physician the approximately a risk name disease both at than and meaningful on excellence agreement should primarily XX agreement with primary burden opportunity a force HLS' Pfizer August of the the XXXX, personnel as believe partner promotion specialist VASCEPA Canada. CVD is Therapeutics, a VASCEPA to With VASCEPA support respected for of China focused existing In patients physicians X in in staff CV of medical branded remain and audience. to in $X primary industry. is selling with there announced Canada, We our a expanding and is China. significant bode field market Canada, market HLS the promotional care care gateway
share thoughts me let around diversification, height on perspective the some dimension. our Finally,
review We all in the obesity cardiometabolic space. continue our potential and systematic of assets
disease spaces, We and in considering remains that where not ourselves populations need. to including alone. the lend primary assets, tremendous are rare care limiting and also unmet unique those We're specialty themselves large there to
of potential assets, with that significantly assets stage transforming and and We assets portfolio. are prioritizing enhancing X types our potential have commercial of near-term development the
this focus due on to can our cardiometabolic time; commercial As scientific, diligence. space, process and requires appreciate the and and primary financial you
With over our future needed believe an is and for let important Mike? resources business, our more We this for Kalb, that our the overview of discussion Mike growth. continue turn detailed of leverage me to are the call this to dedicating financials. a CFO,
